Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. resulting in a patent application for a combination treatment targeting cocaine addiction [1][4] - The patent application is based on preclinical trial results showing that Clearmind's MEAI significantly reduces cocaine-induced craving in animal models [2] - Further research indicates that MEAI specifically targets drug-related compulsions without impairing responses to natural rewards, suggesting a focused mechanism of action [3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals, with ongoing drug development programs targeting various conditions including Tourette Syndrome, Alzheimer's disease, pain, and autism spectrum disorder [5] - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder [6] - Both companies are actively expanding their intellectual property portfolios, with Clearmind holding nineteen patent families and 31 granted patents [7]
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea